Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
Key Financial Performance
Research and Development Revenue $5.1 million, reduced from $7.5 million in the second quarter of last year, reflecting anticipated reduced reimbursements under the BARDA Project BioShield contract.
Gross Margin 45.2%, decreased slightly from 46.6% in the second quarter of last year due to a lower percentage of reimbursed expenses under the Project BioShield BARDA contract.
General and Administrative Expenses $4.4 million, significantly reduced from $5.8 million in the second quarter of 2024, primarily due to continued focus on operating efficiencies and the completion of the de novo submission to the FDA.
Net Loss (Quarterly) $7.9 million, compared to a net loss of $2.9 million in the second quarter of 2024, driven by an increase in the fair value of its publicly traded warrant liability of $5.4 million.
Net Loss (6-Month Period) $5.1 million, reduced from $6.1 million for the first 6 months of last year, a reduction of over $1 million.
Cash and Cash Equivalents $10.5 million as of June 30, 2025, up from $5.2 million on December 31, 2024, primarily due to the company completing its financing.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DeepView System: FDA submission for the DeepView System was completed in Q2 2025. The company is planning a U.S. launch of the system, focusing on burn indications.
Market Expansion: Revenue guidance for 2025 is $21.5 million, excluding potential contributions from DeepView System sales in the UK and Australia, which are not expected to be material for 2025.
Financial Position: The company completed a debt financing agreement of up to $15 million, with an initial draw of $8.5 million, and raised $2.7 million in equity financing. Cash on hand at the end of June 2025 was over $10 million, with potential access to an additional $6.5 million of debt.
Cost Management: General and administrative expenses were reduced from $5.8 million in Q2 2024 to $4.4 million in Q2 2025, reflecting a focus on operational efficiencies.
Strategic Shift: The company is focusing on the commercialization of the DeepView System and has submitted a de novo application to the FDA. Additionally, it is progressing with the IPO of its healthcare intellectual property-focused subsidiary, Spectral IP Inc.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Reduced R&D Revenue: The company's research and development revenue decreased from $7.5 million in Q2 2024 to $5.1 million in Q2 2025, reflecting reduced reimbursements under the BARDA Project BioShield contract. This could impact the company's ability to fund future R&D activities.
Decreased Gross Margin: Gross margin dropped slightly from 46.6% in Q2 2024 to 45.2% in Q2 2025, primarily due to a lower percentage of reimbursed expenses under the BARDA contract. This could affect profitability.
Net Loss Increase: The company reported a net loss of $7.9 million in Q2 2025 compared to $2.9 million in Q2 2024, driven by an increase in the fair value of its publicly traded warrant liability. This indicates financial strain.
Dependence on FDA Approval: The company's future funding and commercialization efforts are heavily reliant on FDA approval of its de novo application. Delays or rejection could significantly impact operations and strategic goals.
Reduced General and Administrative Expenses: While G&A expenses were reduced from $5.8 million in Q2 2024 to $4.4 million in Q2 2025, this reduction may limit resources available for operational and strategic initiatives.
BARDA Contract Dependency: The company’s financial performance is closely tied to the BARDA Project BioShield contract. Any changes or reductions in this contract could adversely affect revenue and operations.
Limited Revenue Diversification: Revenue guidance for 2025 does not include material contributions from sales of the DeepView System in the UK or Australia, indicating limited diversification and reliance on U.S. market success.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Submission and Commercialization: The company has completed its de novo application submission to the FDA in Q2 2025 and expects further interactions with the FDA in the coming months. This submission is a critical step towards the commercialization of the DeepView System, with a planned U.S. launch.
Financial Position and Funding: Spectral AI has over $10 million in cash as of June 2025, with potential access to an additional $6.5 million in debt financing and $7 million in equity upon FDA approval. This funding is expected to support the company’s operations and product commercialization efforts for the foreseeable future.
Revenue Guidance for 2025: The company reiterates its revenue guidance of approximately $21.5 million for 2025. This does not include potential contributions from DeepView System sales in the UK or Australia, which are not expected to be material for 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the timeline for FDA clearance of DeepView and the company's commercialization plans?
A:The company expects FDA clearance for DeepView in the first half of next year, though there is no guarantee. They have developed a thorough commercialization plan, which includes collaboration with BARDA to help roll out the devices and initial purchases upon FDA clearance. They are also exploring a second indication for broader medical applicability.
Q:What potential applications outside of burns is the company exploring for DeepView?
A:The company is exploring applications in wound care and other areas where differentiating non-healing from healing tissue is valuable. This could include traumatic, elective, ischemic, or infected wounds, and may also involve partnerships with companies producing skin substitutes or drugs.
Q:What activities are planned for deployment in the U.K. and Australia?
A:The company is leveraging its existing approval in the U.K. and the positive reception by U.K. burn doctors to gather usage data and lessons for the U.S. market. They are also studying the effort required for more widespread sales in the U.K., including obtaining NICE approval. In Australia, the focus is on usage rather than immediate sales.
Q:What is the regulatory pathway for the Snapshot handheld device?
A:The Snapshot handheld device will follow a 510(k) regulatory pathway using the cart-based device as a predicate. The military has funded the development of a military handheld device, and the company plans to create a parallel pathway for a commercial handheld device.
Q:What is the dialogue with BARDA regarding system rollout post-approval?
A:The company acknowledges that the BARDA contract includes language about helping with the rollout of devices and technology to the community. However, due to uncertainties in the governmental space, the company refrained from providing specific details or predictions about BARDA's actions.
Q:Review of Unclear Management Responses
A:The company avoided providing specific details about BARDA's role in the system rollout post-approval, citing uncertainties in the governmental space. They also used vague language when discussing potential applications outside of burns, emphasizing broad possibilities without concrete examples or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Chairman
AI Financial
AI financing
Assistant General
Avenue Venture
BTIG LLC
Benjamin Zimmerman
CFO General
Cap Research
Capital Group
Capone CFO
Carl Edward
Chairman Chief
Chairman Corporate
Chairman afternoon
Conference speaker
Corporate Participant
Corporate Secretary
Counsel Corporate
DeepView systemize
Division Conference
Division Vandermosten
Dr Chairman
Dr Spectral
ET afternoon
Edward Byrnes
FDA month
FDA novo
FDA partner
Inc
Research Division
entity
finance
hand
novo application
MDAI Transcript
Spectral AI, Inc. (MDAI) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings report shows strong financial performance with significant revenue and net income growth, improved gross margin, and positive cash flow. Despite increased operating expenses, the focus on R&D suggests future growth potential. However, the lack of discussion on strategic initiatives and operational updates, along with the acknowledgment of risks in forward-looking statements, tempers the outlook slightly. Overall, the financial performance suggests a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call summary shows mixed signals: improved net income and cash position are positive, but declining gross margins and R&D revenue are concerns. The Q&A section highlights strategic planning for commercialization but lacks specific details, which raises uncertainty. The absence of guidance adjustments and unclear management responses further contribute to a neutral sentiment. Overall, while there are positive elements, the uncertainties and lack of immediate catalysts keep the stock reaction neutral.
Spectral AI, Inc. (MDAI) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
MDAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
